标签归档：omeprazole

Esomeprazole magnesium salt(Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole magnesium salt (Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole magnesium salt(Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Esomeprazole magnesium salt Chemical Structure

CAS No. : 1198768-91-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole magnesium salt 的其他形式现货产品:

Esomeprazole magnesium trihydrate Esomeprazole sodium Esomeprazole magnesium

生物活性

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

IC50 & Target

H+, K+-ATPase[1][2]
体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Clinical Trial

分子量

369.72

Formula

C17H21MgN3O3S
CAS 号

1198768-91-0
中文名称

埃索美拉唑镁盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Esomeprazole magnesium salt(Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole magnesium salt (Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole magnesium salt(Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Esomeprazole magnesium salt Chemical Structure

CAS No. : 1198768-91-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole magnesium salt 的其他形式现货产品:

Esomeprazole magnesium trihydrate Esomeprazole sodium Esomeprazole magnesium

生物活性

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

IC50 & Target

H+, K+-ATPase[1][2]
体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Clinical Trial

分子量

369.72

Formula

C17H21MgN3O3S
CAS 号

1198768-91-0
中文名称

埃索美拉唑镁盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Esomeprazole magnesium salt(Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole magnesium salt (Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole magnesium salt(Synonyms: (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Esomeprazole magnesium salt Chemical Structure

CAS No. : 1198768-91-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole magnesium salt 的其他形式现货产品:

Esomeprazole magnesium trihydrate Esomeprazole sodium Esomeprazole magnesium

生物活性

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

IC50 & Target

H+, K+-ATPase[1][2]
体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Clinical Trial

分子量

369.72

Formula

C17H21MgN3O3S
CAS 号

1198768-91-0
中文名称

埃索美拉唑镁盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole metabolite Omeprazole sulfone(Synonyms: Omeprazole sulfone; Omeprazole sulphone)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole metabolite Omeprazole sulfone (Synonyms: Omeprazole sulfone; Omeprazole sulphone)

Omeprazole sulfone是Omeprazole的代谢物。

Omeprazole metabolite Omeprazole sulfone(Synonyms: Omeprazole sulfone; Omeprazole sulphone)

Omeprazole metabolite Omeprazole sulfone Chemical Structure

CAS No. : 88546-55-8

规格 价格 是否有货
5 mg ￥1600 询问价格 & 货期
10 mg ￥2700 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

分子量

361.42

Formula

C17H19N3O4S
CAS 号

88546-55-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole metabolite Omeprazole sulfone(Synonyms: Omeprazole sulfone; Omeprazole sulphone)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole metabolite Omeprazole sulfone (Synonyms: Omeprazole sulfone; Omeprazole sulphone)

Omeprazole sulfone是Omeprazole的代谢物。

Omeprazole metabolite Omeprazole sulfone(Synonyms: Omeprazole sulfone; Omeprazole sulphone)

Omeprazole metabolite Omeprazole sulfone Chemical Structure

CAS No. : 88546-55-8

规格 价格 是否有货
5 mg ￥1600 询问价格 & 货期
10 mg ￥2700 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

分子量

361.42

Formula

C17H19N3O4S
CAS 号

88546-55-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole metabolite Omeprazole sulfone(Synonyms: Omeprazole sulfone; Omeprazole sulphone)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole metabolite Omeprazole sulfone (Synonyms: Omeprazole sulfone; Omeprazole sulphone)

Omeprazole sulfone是Omeprazole的代谢物。

Omeprazole metabolite Omeprazole sulfone(Synonyms: Omeprazole sulfone; Omeprazole sulphone)

Omeprazole metabolite Omeprazole sulfone Chemical Structure

CAS No. : 88546-55-8

规格 价格 是否有货
5 mg ￥1600 询问价格 & 货期
10 mg ￥2700 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

分子量

361.42

Formula

C17H19N3O4S
CAS 号

88546-55-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Esomeprazole potassium salt(Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole potassium salt (Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole potassium salt(Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Esomeprazole potassium salt Chemical Structure

CAS No. : 161796-84-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole potassium salt 的其他形式现货产品:

Esomeprazole magnesium trihydrate Esomeprazole sodium Esomeprazole magnesium

生物活性

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

IC50 & Target

H+, K+-ATPase[1][2]
体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Clinical Trial

分子量

383.51

Formula

C17H18KN3O3S
CAS 号

161796-84-5
中文名称

埃索美拉唑钾盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Esomeprazole potassium salt(Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole potassium salt (Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole potassium salt(Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Esomeprazole potassium salt Chemical Structure

CAS No. : 161796-84-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole potassium salt 的其他形式现货产品:

Esomeprazole magnesium trihydrate Esomeprazole sodium Esomeprazole magnesium

生物活性

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

IC50 & Target

H+, K+-ATPase[1][2]
体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Clinical Trial

分子量

383.51

Formula

C17H18KN3O3S
CAS 号

161796-84-5
中文名称

埃索美拉唑钾盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Esomeprazole potassium salt(Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole potassium salt (Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) 是一种有效的具有口服活性质子泵抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole potassium salt(Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Esomeprazole potassium salt Chemical Structure

CAS No. : 161796-84-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole potassium salt 的其他形式现货产品:

Esomeprazole magnesium trihydrate Esomeprazole sodium Esomeprazole magnesium

生物活性

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

IC50 & Target

H+, K+-ATPase[1][2]
体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Clinical Trial

分子量

383.51

Formula

C17H18KN3O3S
CAS 号

161796-84-5
中文名称

埃索美拉唑钾盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole-13CD3(Synonyms: H 16868-13CD3)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole-13CD3 (Synonyms: H 16868-13CD3)

Omeprazole-13CD3 (H 16868-13CD3) 是一种 13C 标记和氘代标记 Omeprazole。Omeprazole (H 16868) 是一种质子泵 (proton pump) 抑制剂 (PPI)，有潜力用于胃肠道疾病的研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。Omeprazole 是中性鞘磷脂酶 (N-SMase) 的抑制剂(外泌体抑制剂)。

Omeprazole-13CD3(Synonyms: H 16868-13CD3)

Omeprazole-13CD3 Chemical Structure

CAS No. : 1261395-28-1

规格 价格 是否有货
1 mg ￥2350 询问价格 & 货期
5 mg ￥10000 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Omeprazole-13CD3 (H 16868-13CD3) is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

349.43

Formula

C1613CH16D3N3O3S
CAS 号

1261395-28-1
中文名称

奥美拉挫 13CD3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.;Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.;Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole sodium(Synonyms: H 16868 sodium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole sodium (Synonyms: H 16868 sodium) 纯度: 98.03%

Omeprazole (H 16868) 是一种质子泵 (proton pump) 抑制剂 (PPI)，有潜力用于胃肠道疾病的研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。Omeprazole 是中性鞘磷脂酶 (N-SMase) 的抑制剂(外泌体抑制剂)。

Omeprazole sodium(Synonyms: H 16868 sodium)

Omeprazole sodium Chemical Structure

CAS No. : 95510-70-6

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥921 In-stock
100 mg ￥837 In-stock
500 mg ￥2100 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Omeprazole sodium 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Metabolism/Protease Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Drug Repurposing Compound Library
  • Antibacterial Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Exosomes Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Lipid Metabolism Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria[2]. Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

体外研究
(In Vitro)

Omeprazole (H 16868) is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. Omeprazole (H 16868) virtually eliminated intragastric acidity in all patients: the median 24 hour intragastric pH rose from 1.4 to 5.3 and the mean hourly hydrogen ion activity fell from 38.50 to 1.95 mmol(mEq)/1 (p less than 0.001). This inhibition of 24 hour intragastric acidity is more profound than that previously reported with either cimetidine 1 g daily or ranitidine 300 mg daily[1]. The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of Omeprazole (H 16868) from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole (H 16868) increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound[2].
Omeprazole sodium is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

367.40

Formula

C17H18N3NaO3S
CAS 号

95510-70-6
中文名称

奥美拉唑钠
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (680.46 mM; Need ultrasonic)

H2O : 5.56 mg/mL (15.13 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7218 mL 13.6091 mL 27.2183 mL
5 mM 0.5444 mL 2.7218 mL 5.4437 mL
10 mM 0.2722 mL 1.3609 mL 2.7218 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.66 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.66 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.66 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

    [2]. Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.

    [3]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole(Synonyms: 奥美拉挫; H 16868)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole (Synonyms: 奥美拉挫; H 16868) 纯度: 98.19%

Omeprazole (H 16868) 是一种质子泵 (proton pump) 抑制剂 (PPI)，有潜力用于胃肠道疾病的研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。Omeprazole 是中性鞘磷脂酶 (N-SMase) 的抑制剂(外泌体抑制剂)。

Omeprazole(Synonyms: 奥美拉挫; H 16868)

Omeprazole Chemical Structure

CAS No. : 73590-58-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥921 In-stock
100 mg ￥837 In-stock
500 mg ￥2100 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Omeprazole 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Metabolism/Protease Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Antibacterial Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Exosomes Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Lipid Metabolism Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

IC50 & Target

Proton Pump[1]
体外研究
(In Vitro)

Omeprazole (H 16868) is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. Omeprazole (H 16868) virtually eliminated intragastric acidity in all patients: the median 24 hour intragastric pH rose from 1.4 to 5.3 and the mean hourly hydrogen ion activity fell from 38.50 to 1.95 mmol(mEq)/1 (p less than 0.001). This inhibition of 24 hour intragastric acidity is more profound than that previously reported with either cimetidine 1 g daily or ranitidine 300 mg daily[1]. The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of Omeprazole (H 16868) from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole (H 16868) increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

345.42

Formula

C17H19N3O3S
CAS 号

73590-58-6
中文名称

奥美拉挫
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (289.50 mM)

H2O : < 0.1 mg/mL (insoluble)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8950 mL 14.4751 mL 28.9503 mL
5 mM 0.5790 mL 2.8950 mL 5.7901 mL
10 mM 0.2895 mL 1.4475 mL 2.8950 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.24 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

    [2]. Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.

    [3]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole metabolite Omeprazole sulfone (methoxy-d3)(Synonyms: Omeprazole sulfone (methoxy-d3); Omeprazole sulphone (methoxy-d3))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole metabolite Omeprazole sulfone (methoxy-d3) (Synonyms: Omeprazole sulfone (methoxy-d3); Omeprazole sulphone (methoxy-d3))

Omeprazole metabolite Omeprazole sulfone (methoxy-d3) (Omeprazole sulfone (methoxy-d3)) 是 Omeprazole metabolite Omeprazole sulfone 的氘代物。Omeprazole sulfone是Omeprazole的代谢物。

Omeprazole metabolite Omeprazole sulfone (methoxy-d3)(Synonyms: Omeprazole sulfone (methoxy-d3); Omeprazole sulphone (methoxy-d3))

Omeprazole metabolite Omeprazole sulfone (methoxy-d3) Chemical Structure

CAS No. : 1189891-71-1

规格 价格 是否有货
1 mg ￥1800 询问价格 & 货期
5 mg ￥7800 询问价格 & 货期
10 mg ￥13500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Omeprazole metabolite Omeprazole sulfone (methoxy-d3) (Omeprazole sulfone (methoxy-d3)) is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

364.43

Formula

C17H16D3N3O4S
CAS 号

1189891-71-1
中文名称

奥美拉挫 d3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

4-Desmethoxy Omeprazole-d3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

4-Desmethoxy Omeprazole-d3 

4-Desmethoxy Omeprazole-d3 是 4-Desmethoxy Omeprazole 的氘代物。4-Desmethoxy Omeprazole 是 Omeprazole 的活性代谢物。Omeprazole 是一种质子泵 (proton pump) 抑制剂 (PPI)，有潜力用于胃肠道疾病的研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。

4-Desmethoxy Omeprazole-d3

4-Desmethoxy Omeprazole-d3 Chemical Structure

CAS No. : 1794759-05-9

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

4-Desmethoxy Omeprazole-d3 is the deuterium labeled 4-Desmethoxy Omeprazole. 4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

318.41

Formula

C16H14D3N3O2S
CAS 号

1794759-05-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

    [3]. Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole metabolite Omeprazole sulfone-d3(Synonyms: Omeprazole sulfone-d3; Omeprazole sulphone-d3)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole metabolite Omeprazole sulfone-d3 (Synonyms: Omeprazole sulfone-d3; Omeprazole sulphone-d3)

Omeprazole metabolite Omeprazole sulfone-d3 (Omeprazole sulfone-d3) 是 Omeprazole metabolite Omeprazole sulfone 的氘代物。Omeprazole sulfone是Omeprazole的代谢物。

Omeprazole metabolite Omeprazole sulfone-d3(Synonyms: Omeprazole sulfone-d3; Omeprazole sulphone-d3)

Omeprazole metabolite Omeprazole sulfone-d3 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Omeprazole metabolite Omeprazole sulfone-d3 (Omeprazole sulfone-d3) is the deuterium labeled Omeprazole metabolite Omeprazole sulfone. Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

364.43

Formula

C17H16D3N3O4S
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole-d3-1(Synonyms: H 16868-d3-1)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole-d3-1 (Synonyms: H 16868-d3-1)

Omeprazole-d3-1 (H 16868-d3-1) 是 Omeprazole 的氘代物。Omeprazole (H 16868) 是一种质子泵 (proton pump) 抑制剂 (PPI)，有潜力用于胃肠道疾病的研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。Omeprazole 是中性鞘磷脂酶 (N-SMase) 的抑制剂(外泌体抑制剂)。

Omeprazole-d3-1(Synonyms: H 16868-d3-1)

Omeprazole-d3-1 Chemical Structure

CAS No. : 934293-92-2

规格 价格 是否有货
1 mg ￥3600 询问价格 & 货期
5 mg ￥10800 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Omeprazole-d3-1 (H 16868-d3-1) is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

348.43

Formula

C17H16D3N3O3S
CAS 号

934293-92-2
中文名称

奥美拉挫 d3-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

    [3]. Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.

    [4]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Omeprazole-d3(Synonyms: 奥美拉挫 D3; H 16868-d3)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Omeprazole-d3 (Synonyms: 奥美拉挫 D3; H 16868-d3) 纯度: 98.99%

Omeprazole D3 (H 16868 D3) 是 Omeprazole 的氘代物。Omeprazole 是一种质子泵 (proton pump) 抑制剂 (PPI)，可用于胃肠道疾病的相关研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。

Omeprazole-d3(Synonyms: 奥美拉挫 D3; H 16868-d3)

Omeprazole-d3 Chemical Structure

CAS No. : 922731-01-9

规格 价格 是否有货 数量
1 mg ￥1800 In-stock
5 mg ￥6800 In-stock
10 mg ￥11500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

Omeprazole D3 (H 16868 D3) is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

分子量

348.43

Formula

C17H16D3N3O3S
CAS 号

922731-01-9
中文名称

奥美拉挫 d3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (358.75 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8700 mL 14.3501 mL 28.7002 mL
5 mM 0.5740 mL 2.8700 mL 5.7400 mL
10 mM 0.2870 mL 1.4350 mL 2.8700 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.97 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.97 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.97 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.97 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

    [2]. Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

4-Desmethoxy Omeprazole

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

4-Desmethoxy Omeprazole 

4-Desmethoxy Omeprazole 是 Omeprazole 的活性代谢物。Omeprazole 是一种质子泵 (proton pump) 抑制剂 (PPI)，有潜力用于胃肠道疾病的研究。Omeprazole 竞争性抑制 CYP2C19 活性，Ki 为 2 到 6 μM。Omeprazole 还抑制革兰氏阳性菌和革兰氏阴性菌生长。

4-Desmethoxy Omeprazole

4-Desmethoxy Omeprazole Chemical Structure

CAS No. : 110374-16-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

分子量

315.39

Formula

C16H17N3O2S
CAS 号

110374-16-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.

    [2]. Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Esomeprazole hemistrontium(Synonyms: (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Esomeprazole hemistrontium (Synonyms: (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium)

Esomeprazole ((S)-Omeprazole) hemistrontium 是一种有效的具有口服活性质子泵 (proton pump) 抑制剂，可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole hemistrontium(Synonyms: (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium)

Esomeprazole hemistrontium Chemical Structure

CAS No. : 914613-86-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Esomeprazole hemistrontium 的其他形式现货产品:

Esomeprazole magnesium Esomeprazole magnesium trihydrate Esomeprazole sodium

生物活性

Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

体外研究
(In Vitro)

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) hemistrontium treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

体内研究
(In Vivo)

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) hemistrontium treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

分子量

388.22

Formula

C17H18N3O3SSr+
CAS 号

914613-86-8
中文名称

埃索美拉唑锶
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

    [2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

    [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务